Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

EVP Chief Operating Officer

Chief Executive Officer

EVP Chief Medical Officer

Chief People & Workpl Officer

EVP Technical Operations

EVP Genl Counsel & Secretary

Chief Financial Officer

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DP Treprostinil, an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease, and idiopathic pulmonary and cystic fibrosis. In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for en...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-03-27	Premium	sold (taxes)	Premium	Premium	Premium	EVP Chief Operating Officer
2024-02-04	Premium	acquired	Premium	Premium	Premium	Chief Executive Officer
2024-02-04	Premium	acquired	Premium	Premium	Premium	-
2024-02-04	Premium	acquired	Premium	Premium	Premium	EVP Chief Medical Officer
2024-02-04	Premium	acquired	Premium	Premium	Premium	Chief People & Workpl Officer
2024-02-04	Premium	acquired	Premium	Premium	Premium	-
2024-02-04	Premium	acquired	Premium	Premium	Premium	-
2024-02-04	Premium	acquired	Premium	Premium	Premium	EVP Chief Operating Officer
2023-12-31	Premium	acquired	Premium	Premium	Premium	Chief People & Workpl Officer
2023-12-31	Premium	acquired	Premium	Premium	Premium	EVP Chief Operating Officer
2023-12-31	Premium	acquired	Premium	Premium	Premium	EVP Chief Medical Officer
2023-12-31	Premium	acquired	Premium	Premium	Premium	Chief Executive Officer
2023-12-15	Premium	sold	Premium	Premium	Premium	Chief Executive Officer
2023-12-14	Premium	sold	Premium	Premium	Premium	Chief Executive Officer
2023-11-01	Premium	sold	Premium	Premium	Premium	Chief Executive Officer
2023-10-31	Premium	sold (taxes)	Premium	Premium	Premium	EVP Technical Operations
2023-10-02	Premium	sold	Premium	Premium	Premium	Chief Executive Officer
2023-10-02	Premium	sold	Premium	Premium	Premium	Chief Executive Officer
2023-09-05	Premium	sold	Premium	Premium	Premium	Chief Executive Officer
2023-09-01	Premium	sold	Premium	Premium	Premium	Chief Executive Officer
2023-08-28	Premium	sold	Premium	Premium	Premium	EVP Genl Counsel & Secretary
2023-08-27	Premium	sold (taxes)	Premium	Premium	Premium	Chief Financial Officer
2023-08-27	Premium	sold (taxes)	Premium	Premium	Premium	Chief People & Workpl Officer
2023-08-27	Premium	sold (taxes)	Premium	Premium	Premium	Chief Executive Officer
2023-08-27	Premium	sold (taxes)	Premium	Premium	Premium	EVP Genl Counsel & Secretary

MNKD - MannKind Corp Stock Price, Fair Value and News

Latest Insider Trading transactions for MNKD